Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.88 -0.44 (-0.43%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks. 
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance. 
Via Benzinga
Is Merck Stock a Buy?
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better. 
Via The Motley Fool
Merck (MRK) Q3 2024 Earnings Call Transcript
MRK earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Merck Q3 Earnings And Revenues Top Estimates
Merck came out with quarterly earnings of $1.57 per share. 
Via Talk Markets
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
A Look Into Merck & Co Inc's Price Over Earnings
Via Benzinga
Where Will Merck Be in 5 Years?
There's a lot to like here. 
Via The Motley Fool
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts. 
Via Benzinga
Will Merck's Guidance Cut Prove Gruesome In The Wake Of Januvia, Gardasil Misses?
The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet. 
Via Investor's Business Daily
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Is NYSE:MRK a Good Fit for Dividend Investing?
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
3 Dividend Stocks That Could Raise Their Payouts in November
These dividend stocks can be excellent options for buy-and-hold investors. 
Via The Motley Fool
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... 
Via Benzinga
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... 
Via Benzinga
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV. 
Via Benzinga
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
Exposures Product Safety
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks. 
Via The Motley Fool
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.